证券代码：688067 证券简称：爱威科技 公告编号：2025-019 爱威科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 05 月 23 日 （二） 股东大会召开的地点：湖南省长沙市岳麓区学士街道茯苓路 26 号公司 319 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 19 | | --- | --- | | 普通股股东人数 | 19 | | 2、出席会议的股东所持有的表决权数量 | 35,118,629 | | 普通股股东所持有表决权数量 | 35,118,629 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 52.1992 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 52.1992 | （四 ...

湖南启元律师事务所 二〇二五年五月 湖南省长沙市芙蓉区建湘路 393 号世茂环球金融中心 63 层 410005 电话：（0731）82953-778 传真：（0731）82953-779 网站：www.qiyuan.com 湖南启元律师事务所 HUNAN QIYUAN LAW FIRM 湖南省长沙市芙蓉区建湘路 393 号 世茂环球金融中心 63 层 410005 Tel：(0731) 8295 3778 Fax：(0731) 8295 3779 http://www.qiyuan.com 湖南启元律师事务所 关于爱威科技股份有限公司 2024 年年度股东大会的法律意见书 致：爱威科技股份有限公司 关于 爱威科技股份有限公司 2024年年度股东大会的 法律意见书 2、出席会议的股东或其代理人的身份证明文件、持股证明文件、授权委托书 等； 湖南启元律师事务所（以下简称"本所"）接受爱威科技股份有限公司（以 下简称"公司"）的委托，指派本所律师出席了公司 2024 年年度股东大会（以下 简称"本次股东大会"），对本次股东大会的召集和召开程序、出席会议人员资 格、表决程序和表决结果的合法有效性进行现场律师见证，并 ...

Core Viewpoint - The company is focused on expanding its AI image recognition technology applications in various medical testing fields, aiming to become a comprehensive service provider in medical laboratory equipment and related products [2][3]. Company Development and Technology - The company has diversified its product line in the medical testing instrument sector and is applying its core technology to blood, body fluid, pathology, and microbiological testing [2]. - The company has established a competitive advantage in the automation of clinical specimen microscopic examination, having entered this technology field early and developed a leading medical microscopic image database [4][5]. Industry Outlook - The high-end medical device industry is expected to have broad development prospects driven by national import substitution policies, technological innovation, and globalization strategies [3]. - The integration of artificial intelligence technology with modern diagnostic medicine is anticipated to accelerate the shift towards intelligent diagnostics in various fields [12]. Financial Performance - In 2024, the company achieved a net profit of 22.84 million yuan, a year-on-year increase of 6.07%, with a significant increase in net profit excluding non-recurring gains of 24.99% [10]. - For Q1 2025, the company reported a net profit of 6.32 million yuan, up 24.63% year-on-year, and a net profit of 5.01 million yuan after excluding non-recurring gains, reflecting a 48.77% increase [10][13]. Market Strategy - The company plans to maintain continuous R&D investment and product updates to sustain its competitive edge in the industry [8]. - Future growth drivers include expanding into new customer segments, particularly in grassroots and civilian markets, as well as international markets [8]. Product Applications - The company is leveraging machine vision and deep learning technologies to automate the analysis of microscopic components in clinical specimens, significantly improving accuracy and efficiency [5]. - The company is also exploring applications of its technology in non-medical fields such as aquatic biological detection and mineral testing [9].

爱威科技股份有限公司 2024 年年度股东大会会议资料 爱威科技股份有限公司 2024年年度股东大会会议资料 二〇二五年五月 爱威科技股份有限公司 2024 年年度股东大会会议资料 目 录 | 2024年年度股东大会会议须知 1 | | --- | | 2024年年度股东大会会议议程 3 | | 议案一：《关于公司<2024年度董事会工作报告>的议案》 5 | | 议案二：《关于公司<2024年度监事会工作报告>的议案》 10 | | 议案三：《关于公司<2024年度财务决算报告>的议案》 13 | | 议案四：《关于公司2024年年度报告及其摘要的议案》 17 | | 议案五：《关于公司2024年度利润分配方案的议案》 18 | | 议案六：《关于公司2025年中期分红安排的议案》 20 | | 议案七：《关于续聘公司2025年度审计机构的议案》 21 | | 议案八：《关于公司2025年度董事薪酬的议案》 22 | | 议案九：《关于公司2025年度监事薪酬的议案》 23 | | 议案十：《关于公司募集资金投资项目变更、结项及延期并将节余募集资金永久 | | 补充流动资金的议案》…… … 24 | | 听 ...

Company Overview - Awei Technology Co., Ltd. specializes in the research, development, production, sales, and service of medical clinical testing analysis instruments and in vitro diagnostic reagents, as well as medical consumables [1] - The company has developed a series of medical testing instruments based on original automatic microscopy technology, including automatic urine, feces, and reproductive tract secretion analyzers [1] Financial Performance - For Q1 2025, the company reported revenue of 53.30 million yuan, a year-on-year increase of 13.85%, and a net profit of 6.32 million yuan, up 24.63% year-on-year [2] - The sales gross margin for the company stands at 55.59% [2] Market Position - As of May 12, Awei Technology's stock closed at 19.98 yuan, with a rolling price-to-earnings (PE) ratio of 56.40, marking a new low in 36 days [1] - The average PE ratio for the medical device industry is 49.84, with a median of 36.59, placing Awei Technology at the 90th position in the industry ranking [1][2] Shareholder Information - As of March 31, 2025, the number of shareholders for Awei Technology is 3,605, a decrease of 14 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

Core Viewpoint - The IVD industry is experiencing a significant downturn in revenue and profits, with over 70% of companies reporting a year-on-year decline in revenue and more than half facing losses or drastically reduced profits [2][5]. Revenue and Profit Trends - In Q1 2025, major IVD companies such as Mindray Medical, Dian Diagnostics, and RunDa Medical reported substantial declines in both revenue and net profit, with Mindray's revenue at 8.237 billion yuan (down 12.12%) and net profit at 2.629 billion yuan (down 16.81%) [2][4]. - Among 60 IVD companies analyzed, 16 reported revenue growth, with 8 achieving both revenue and net profit growth [2]. Market Challenges - The IVD sector is facing multiple challenges, including a slowdown in the conventional medical testing market, stricter cost control policies in healthcare, and the impact of centralized procurement policies [5][6]. - The anticipated centralized procurement in 28 provinces is expected to further pressure IVD companies, particularly in the high-volume chemical luminescence market [6]. Company Strategies and Innovations - Some companies are adapting by focusing on niche markets and innovative product offerings, such as New Industry and Sansure Bio, which reported revenue growth of 10.12% and 21.62% respectively in Q1 2025 [9]. - Companies are also exploring international markets, with Mindray's overseas revenue reaching 16.43 billion yuan in 2024, accounting for 44.75% of total revenue [9][10]. Technological Advancements - The IVD industry is witnessing a shift towards digitalization and AI integration, with partnerships like that of BGI and Dian Diagnostics aiming to enhance diagnostic efficiency and precision [10][11]. - The emergence of AI technologies is reshaping the IVD landscape, although challenges remain in data integration and commercialization [11].

爱威科技股份有限公司 关于召开2024年度暨2025第一季度业绩说明会的公告 证券代码：688067 证券简称：爱威科技 公告编号： 2025-018 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 本次投资者说明会以网络互动形式召开，公司将针对 2024 年度及 2025 年第一 季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露 允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2025 年 05 月 19 日 （星期一） 15:00-16:00 会议召开时间：2025 年 05 月 19 日 （星期一） 15:00-16:00 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.ssei nfo.com/） 会议召开方式：上证路演中心网络互动 （二） 会议召开地点：上海证券交易所上证路演中心 （三） 会议召开方式：上证路演中心网络互动 三、 参加人员 董事长、总经理：丁建文先生 董事、副总经理：林常青 ...

爱威科技股份有限公司是一家主营业务为医疗临床检验分析仪器及配套体外诊断试剂、医用耗材的研 发、生产、销售和服务一体化的高新技术企业。公司基于原创性医学显微镜自动镜检技术开发出全自动 尿液、粪便、生殖道分泌物等多系列医学检验仪器,并自主开发生产与检验仪器相配套的试剂及医用耗 材产品。公司的主要产品有尿液有形成分分析仪、尿液干化学分析仪、尿全项自动分析仪、全自动粪便 分析仪、全自动体液分析仪、生殖道分泌物分析仪、专用配套体外诊断试剂、医用耗材。公司获得 了"国家知识产权示范企业"、"国家知识产权优势企业"、"中国专利优秀奖(图像处理方法和装置)"等多 项荣誉奖项。 5月6日，爱威科技今日收盘19.48元，上涨3.78%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到54.99倍，创30天以来新低，总市值13.25亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均48.90倍，行业中值36.41倍，爱威科技排 名第89位。 截至2025年一季报，共有5家机构持仓爱威科技，其中其他3家、基金2家，合计持股数543.66万股，持 股市值0.98亿元。 来源：金融界 最新一期业绩显示，2025年 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 （五）审议通过《关于公司2025年第一季度报告的议案》 具体内容请详见公司同日刊载于上海证券交易所网站（www.sse.com.cn）的《爱威科技股份有限公司 2025年第一季度报告》。本议案已经公司董事会审计委员会审议通过。 表决情况：7票同意，0票反对，0票弃权。 （六）审议通过《关于公司2024年度利润分配预案的议案》 具体内容请详见公司同日刊载于上海证券交易所网站（www.sse.com.cn）的《爱威科技股份有限公司关 于公司2024年年度利润分配预案的公告》。 表决情况：7票同意，0票反对，0票弃权。 具体内容请详见公司同日刊载于上海证券交易所网站（www.sse.com.cn）的《爱威科技股份有限公司关 于公司2025年中期分红安排的公告》。 表决情况：7票同意，0票反对，0票弃权。 本议案尚需提交公司2024年年度股东大会审议。 （八）审议通过《关于制定公司部分治理制度的议案》 为进一步促进公司规范运作，建立健全内部治理机制，公司拟新制定《舆情应对管理制度》《会计师事 务所选聘制度》《董事、监事、高级管理人员和核心技术人员所持本公司股份及其变动 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Aiwei Technology, which operates in the medical device industry [1][2] - As of April 28, Aiwei Technology's stock closed at 17.85 yuan, down 1.60%, with a rolling PE ratio of 52.83 times and a total market capitalization of 1.214 billion yuan [1] - The average PE ratio for the medical device industry is 46.40 times, with a median of 34.81 times, placing Aiwei Technology at the 89th position in the industry ranking [1][2] Group 2 - For the first quarter of 2025, Aiwei Technology reported an operating income of 53.2953 million yuan, representing a year-on-year increase of 13.85%, and a net profit of 6.3210 million yuan, up 24.63% [2] - The company's sales gross margin stands at 55.59% [2] - Aiwei Technology specializes in the research, development, production, and sales of medical clinical testing analysis instruments and related in vitro diagnostic reagents, with a range of products including automated urine analyzers and fecal analysis instruments [1]